EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Adverum Biotechnologies's Enterprise Value is $213.46 Mil.
Adverum Biotechnologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-123.99 Mil. Therefore, Adverum Biotechnologies's EV-to-EBIT for today is -1.72.
The historical rank and industry rank for Adverum Biotechnologies's EV-to-EBIT or its related term are showing as below:
ADVM'
s EV-to-EBIT Range Over the Past 10 Years
Min: -67.4 Med: -0.37 Max: 3.2
Current: -1.72
During the past 12 years, the highest EV-to-EBIT of Adverum Biotechnologies was 3.20. The lowest was -67.40. And the median was -0.37.
ADVM's EV-to-EBIT is ranked worse than 100% of 440
companies
in the Biotechnology industry
Industry Median: 8.685
vs ADVM: -1.72
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Adverum Biotechnologies's Enterprise Value for the quarter that ended in Dec. 2023 was $54.87 Mil.
Adverum Biotechnologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-123.99 Mil. Adverum Biotechnologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -225.98%.
Adverum Biotechnologies EV-to-EBIT Historical Data
The historical data trend for Adverum Biotechnologies's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Adverum Biotechnologies Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBIT
-9.36
-5.58
0.20
0.13
-0.44
Adverum Biotechnologies Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBIT
0.13
-0.04
-0.80
-0.83
-0.44
Competitive Comparison
For the Biotechnology subindustry, Adverum Biotechnologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adverum Biotechnologies EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Adverum Biotechnologies's EV-to-EBIT falls into.
Adverum Biotechnologies EV-to-EBIT Calculation
Adverum Biotechnologies's EV-to-EBIT for today is calculated as:
Adverum Biotechnologies's current Enterprise Value is $213.46 Mil.
Adverum Biotechnologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Adverum Biotechnologies's Enterprise Value for the quarter that ended in Dec. 2023 was $54.87 Mil.
Adverum Biotechnologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adverum Biotechnologies EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Adverum Biotechnologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Adverum Biotechnologies (Adverum Biotechnologies) Business Description
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADVM has been successfully added to your 